Efficacy and safety of intranasal haloperidol in an acute Psychiatry Unit: a pilot study on schizophrenic patients with mild-modedate agitation.

Autor:	Duñó Ambròs R; Mental Health Service, Parc Taulí University Hospital, Autonomous University of Barcelona, CIBERSAM Translational Neuroscience Unit, Parc Taulí University Hospital, Autonomous University of Barcelona, Sabadell, Barcelona., Oliva Morera JC; Statistics and Evaluation Unit, Parc Taulí Research and Innovation Institute, Autonomous University of Barcelona, Sabadell, Barcelona., Iglesias-Lepine ML; Emergency Services, Hospital Nuestra Señora de los Reyes, Valverde, El Hierro., Palao Vidal D; Mental Health Service, Parc Taulí University Hospital, Autonomous University of Barcelona, CIBERSAM Translational Neuroscience Unit, Parc Taulí University Hospital, Autonomous University of Barcelona, Sabadell, Barcelona., Monreal Ortiz JAMO; Mental Health Service, Parc Taulí University Hospital, Autonomous University of Barcelona, CIBERSAM Translational Neuroscience Unit, Parc Taulí University Hospital, Autonomous University of Barcelona, Sabadell, Barcelona., Labad Arias J; Mental Health Service, Parc Taulí University Hospital, Autonomous University of Barcelona, CIBERSAM Translational Neuroscience Unit, Parc Taulí University Hospital, Autonomous University of Barcelona, Sabadell, Barcelona.
Jazyk:	angličtina
Zdroj:	Actas espanolas de psiquiatria [Actas Esp Psiquiatr] 2021 Sep; Vol. 49 (5), pp. 205-209. Date of Electronic Publication: 2021 Sep 01.
Abstrakt:	To study the efficacy and safety of intranasal administration of 5 mg haloperidol on mild-moderate agitated patients with schizophrenia or schizoaffective disorder in an acute psychiatry unit setting.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu